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Protocol
AbstrACt
Introduction The first birth cohorts of women offered 
human papillomavirus (HPV) vaccination as girls are 
now entering cervical screening. However, there is no 
international consensus on how to screen HPV vaccinated 
women. These women are better protected against 
cervical cancer and could therefore be offered less 
intensive screening. Primary HPV testing is more sensitive 
than cytology, allowing for a longer screening interval. The 
aim of Trial23 is to investigate if primary HPV testing with 
cytology triage of HPV positive samples is a reasonable 
screening scheme for women offered HPV vaccination as 
girls.
Methods Trial23 is a method study embedded in the 
existing cervical screening programme in four out of 
five Danish regions. Without affecting the screening 
programme, women born in 1994 are randomised to 
present screening with liquid-based cytology every third 
year (present programme arm) or present screening plus 
an HPV test (HPV arm). The study started 1 February 2017 
and will run over three screening rounds corresponding to 
7–8 years.
Analyses The primary endpoint is cervical intraepithelial 
neoplasia grade 3 or above. The trial is undertaken as 
a non-inferiority study including intention-to-treat and 
per-protocol analyses. The potential effect of primary HPV 
screening with a 6-year interval will be calculated from the 
observed data.
Ethics and dissemination The study protocol has 
been submitted to the ethical committee and deemed 
a method study. All women are screened according to 
routine guidelines. The study will contribute new evidence 
on the future screening of HPV vaccinated birth cohorts 
of women. All results will be published in open-access 
journal.
trial registration NCT03049553; Pre-results.
IntroduCtIon 
There are two preventive measures against 
cervical cancer: the long-time practised 
cervical cancer screening aiming to find 
precancerous lesions before they develop into 
invasive cancer and the newer vaccination 
against human papillomavirus (HPV), 
a necessary cause of cervical cancer.1 In 
Denmark, as well as in many other countries, 
both measures are used. However, there is no 
international consensus on the best way to 
combine the two. Trial23 aims to contribute 
in answering this question.
In 2016, the first birth cohort of Danish 
women offered HPV vaccination as girls 
entered the cervical screening programme. 
So far, the national recommendations 
for cervical screening have not changed. 
Denmark was among the first countries to 
introduce HPV vaccination and is conse-
quently one of the first countries to face the 
challenge of how to screen HPV vaccinated 
women. Trial23 aims to optimise screening 
for women offered HPV vaccination as girls.
In 2008, Danish girls born in 1993–1995 
were offered free HPV vaccination with 
the quadrivalent Gardasil (Merck). They 
were 13–15 years old at the time. Since 
2009, HPV vaccination has been part of the 
Danish child vaccination programme for 
12-year-old girls.2 The vaccine high risk (HR) 
HPV types 16 and 18 are present in 70% 
of cervical cancers.3 Vaccine studies have 
shown a protection of almost 100% against 
vaccine type (HPV 16 and 18) related cervical 
intraepithelial neoplasia (CIN) 2+ in women 
HPV naive at the time of vaccination4 5 and a 
protection of 43% against all CIN2+.6 As HPV 
strengths and limitations of this study
 ► Embedded in the existing cervical screening 
programme.
 ► Cross-regional study including large number of 
women.
 ► Six-year screening interval in human papillomavi-
rus arm estimated based on observed data.
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is a sexually transmitted infection, vaccination should 
preferably take place before sexual debut.
Cervical screening in Denmark targets women aged 
23–64 years. From ages 23– to 49 years, women are 
offered cytology-based screening every third year, and for 
50 years and above, every fifth year. Liquid-based cytology 
is used nationwide. Women above age 60 years are offered 
an HPV-DNA ‘exit-test’.7 Most of the samples are taken 
in general practice. Coverage is about 75% for all age 
groups8 and around 60% for women aged 23–24 years.9
Several countries are implementing primary 
HPV testing, such as Australia, New Zealand, Sweden 
and the Netherlands.10–13 Primary HPV testing has been 
compared with cytology in large randomised controlled 
trials (RCTs) showing that HPV testing provides a better 
protection against cervical cancer.14 Indeed, the 6-year 
protection against CIN3+ after a negative HPV test was 
higher than the 3-year protection after a negative cytology 
test.15 For young women, data from A Randomised Trial 
In Screening To Improve Cytology (ARTISTIC) trial 
show similar results.16 However, the European Guidelines 
recommend against primary HPV screening in women 
younger than 30 years because of a risk of increased 
overdiagnosis and referral for colposcopy.17 This is due 
to a high HPV prevalence combined with a high regres-
sion rate of lesions in young women.18 A Danish study 
estimated that 46% of unvaccinated Danish women aged 
20–23 years have an HR HPV infection.19 This under-
lines the need for triage in primary HPV testing of young 
women.
objective
Women HPV vaccinated as girls are better protected against 
cervical cancer than previous birth cohorts. HPV vaccina-
tion is expected to prevent 70% of cervical cancers. So even 
in these women, some screening may still be beneficial. It is 
therefore pertinent to find less intensive screening schemes 
for women HPV vaccinated as girls.
The objective of this study is to investigate if primary 
HPV testing with cytology triage every 6 years protects women 
offered HPV vaccination as girls against CIN3+ to the same 
extent as the current cytology-based screening every 3 years. 
The longer screening interval would reduce the burden of 
screening in HPV-negative women by reducing the number 
of screening rounds. In this way the screening programme 
could take into account that the optimal balance between 
screening-related harms and gains differs between HPV-vac-
cinated women and previous birth cohorts.
Hypothesis
No difference between cumulative risk of CIN3+ after two 
rounds of primary HPV screening with cytology triage and 
three rounds of cytology-based screening (present screening 
programme).
MEtHods And AnAlysIs
Trial23 is a method study embedded in the Danish cervical 
screening programme.
Originally, the intention was to compare the present 
screening method (cytology) to primary HPV testing 
with cytology triage with different time intervals. 
However, the Danish Ethical Committee required 
informed consent for permission to randomise 
screening scheme. Collection of informed consent was 
not feasible due to the large number of participants 
and decentralised sampling procedure. For this reason, 
the trial is undertaken as a method study as defined 
by the Danish Ethical Committees. However, although 
the design has changed, the objective of the trial is 
unchanged, and the comparison between the two envi-
sioned schemes will be calculated from the collected 
data. We therefore operate with the terms ‘HPV’ and 
‘present program arm’.
In the method study, the HPV test is made as a cotest 
on the cytology sample material without affecting the 
screening programme. The HPV test does not affect the 
clinical management of the woman.
study design
Women are randomly allocated 1:1 for HPV or present 
programme arm:
 ► HPV arm: cytology and HPV-test every third year.
 ► Present programme arm: cytology every third year
There are four possible scenarios for women in the 
HPV-arm (see figure 1):
 ► HPV-negative, cytology normal.
 ► HPV-negative, cytology abnormal.
 ► HPV-positive, cytology normal.
 ► HPV-positive, cytology abnormal.
Among these scenarios only the HPV-negative/cytology 
abnormal differs from primary HPV screening with 
cytology triage. In this case, cytology triage would not 
have been performed and abnormal cytology would not 
have been found.
In the present screening programme, all regions refer 
women with high-grade cytology changes to colpos-
copy and biopsy. In case of low-grade cytology changes, 
some regions use HPV triage, while others recommend 
cytology control after 6 months. These regional practices 
are incorporated into the HPV arm (see figure 1).
In order to avoid increased referral for colposcopy 
and overdiagnosis when young women are screened with 
HPV tests, the cytology determines the course of action. 
A woman with a positive HPV test and normal cells at 
baseline is retested for both HPV and cytology in the 
next round 3 years later, as in the new Swedish cervical 
screening programme.11
setting
The study is set in four out of five Danish regions: Central 
Denmark Region, North Denmark Region, Region 
Zealand and part of Region of Southern Denmark (see 
figure 2). Cervical screening is centralised to one or a few 
pathology departments in each region.
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timeline
Trial23 commenced on 1 February 2017 and will run over 
three screening rounds, that is, 7–8 years (see table 1). The 
final results will be analysed when follow-up is completed. 
Results of the baseline screening round will be analysed 
after 1 October 2018 allowing for at least 3 months from 
invitation to screening and 6 months for follow-up in case 
of abnormal screening result.
target population
Women born in 1994 turning 23 years in 2017 and living 
in the geographical areas covered by the trial form the 
target population (see table 2). These women were 
14 years old when they were offered HPV vaccination, 
and more than 80% of them had at least one dose.20 
According to a Danish school survey, 76% had not had 
their sexual debut and are therefore expected to have 
been HPV naïve at the time of vaccination.21
Eligibility criteria
Inclusion criteria
Women born in 1994 and living in the geographical areas 
covered by the trial are automatically included.
Exclusion criteria
None.22
randomisation
All persons ever living in Denmark have a personal iden-
tification number (PIN) and are included in the Danish 
Central Person Register (CPR). The PIN is registered at 
all contacts to the healthcare system. PINs for women 
born in 1994 and living in Denmark in January 2017 were 
obtained from the CPR.
These women were individually randomised to HPV 
or present programme arm, and this allocation was 
loaded onto the pathology IT systems of the participating 
pathology departments.
Randomisation is based on birth year instead of partic-
ipation in screening, because we want to include all 
women to allow for intention-to-treat analysis. Women are 
not randomised by region in spite of the small regional 
differences in management and follow-up (figure 1). 
Young women tend to be mobile, and we therefore prefer 
to stratify the results by region afterwards.
When a cytology sample from a randomised woman is 
received at a laboratory and scanned into the IT system, 
a ‘pop-up’ message appears on the screen. The ‘pop-up’ 
message shows that the woman is included in Trial23 
and informs if an HPV test should be performed. A 
specific project code is assigned at registration.
blinding
The trial is unblinded.
outcome measures
Primary outcome
How many cases of CIN3+ seen over two rounds of 
HPV screening with cytology triage with a 6 years 
interval, including follow-up after 3 years of women 
HPV-positive and cytology normal at baseline, would 
have been seen over three rounds of cytology screening 
with a 3-year interval.
CIN3+ is chosen as primary outcome because the 
Danish Society of Gynecology and Obstetrics23 at this 
stage always recommends Large Loop Excision of the 
Transformation Zone (LLETZ).
Figure 1 Trial flow for participation in cervical screening. *Abnormal cytology, high grade: HSIL, ASCH and AIS (Bethesda 
classification). **Abnormal cytology, low grade: ASCUS, AGC and LSIL (Bethesda classification). ***Colposcopy with 
biopsy. AGC, atypical glandular cells; AIS, adenocarcinoma in situ; ASCH, atypical squamous cells cannot exclude; ASCUS, 
atypical squamous cells of undetermined significance; HPV, human papillomavirus; HSIL, high grade squamous intraepithelial 
lesions; LSIL, low grade squamous intraepitehlial lesions.
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Secondary outcomes
Number of colposcopies and number of LLETZs observed 
over three rounds of cytology screening and estimated over 
two rounds of HPV screening with cytology triage.
Other outcomes
Baseline screening results.
Intervention
There is no real intervention in this study as it is a method 
study, and the result of the HPV test does not affect the clin-
ical management of the woman. However, in the interven-
tion arm, an HPV test is performed in addition to routine 
cytology screening. Cobas 4800 HPV-DNA test (Roche) 
is used in the trial, because it was already in routine use 
in the participating pathology departments. There was 
therefore no need for special training or extra equipment. 
Roche sponsors test kits for the trial. Cobas is a PCR test 
and detects 14 HR HPV types. It operates with three signals: 
HPV-16, HPV-18 and ‘HPV-other’ covering the remaining 
12 HR HPV-types (31,33,35,39,45,51,52,56,58,59,66, 
68).24 Standard laboratory requirements from the manufac-
turer are followed. As part of the trial, cervical biopsies are 
analysed with CINtec p16 Histology (Roche)25 in addition 
to the routine pathology reading. Roche sponsors the p16 
test kits.
data analysis plan
The trial is undertaken as a non-inferiority study. If 
non-inferiority is proved, analysis for superiority will 
be carried out. Incidence rate ratios for outcomes will 
be calculated using Poisson regression analysis and SAS 
statistical software. We plan two types of analysis. First, an 
intention-to-treat analysis (ITT) including all randomised 
Figure 2 Map over the geographical areas covered by Trial23.
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women followed from study start on 1 February 2017 
until censoring due to death, emigration, event or 
end-of-study. Second, a per-protocol analysis including 
only screened women. Follow-up of this group will start 
on the date of their first cytology sample and end at 
censoring due to death, emigration, event or end-of-study 
as in the ITT population. The analyses will be stratified 
by HPV vaccination status and region of residence. The 
expected outcome of primary HPV screening with cytology 
triage will be estimated by including CIN3+ lesions found 
over the 7 years of follow-up. For the envisioned primary 
HPV screening with cytology triage, we will include 
CIN3+ lesions in women HPV-positive/cytology abnormal 
at baseline; HPV-positive/cytology normal at baseline, but 
HPV-positive/cytology abnormal at re-testing after 3 years; 
or HPV-positive/cytology abnormal at re-screening after 6 
years. For the routine cytology screening, we will include 
CIN3+ lesions in women cytology abnormal, at either the 
baseline screen, at second screen after 3 years or at third 
screen after 6 years.
Power calculation
The power calculation was based on the number of 
23-year-old women residing in the geographic areas 
covered by the trial. We expect 60% of 23-year-old girls 
to participate in the screening programme.9 Based on 
experience from women born in 1983, we expect 1% of 
the screened women to be diagnosed with CIN3+ at the 
first screening,26 and we expect 80% of the women 
to be HPV vaccinated.20 Furthermore, we expect the 
HPV vaccine efficacy for all CIN3+ to be 43%.6 If there 
truly is no difference between the intervention and the 
present programme in our trial population, the upper 
limit of a one-sided 95% CI will exclude a difference of 
more than 0.35% with a power of 80% and a difference 
of 0.4% with a power of 90%. We expect approximately 
12 000 women born in 1994 to be included in the trial, 
with 6000 women in each arm.
data sources
Data on the screening tests (cervical cytologies and 
HPV tests) and other screening-related outcomes for 
women assigned a project code will be retrieved from 
the Danish Pathology register and other national health 
registers. Use of PINs ensures that there is almost no loss 
to follow-up and makes it possible to merge data from 
different registers for the study population.
Table 1 SPIRIT flow chart for Trial23
Study period
Enrolment/
allocation
Postallocation
Close-outBaseline screen Second screen Third screen 
Timepoint January 2017* February 2017–
September 2018
January 2020–
September 2021 
January 2023– 
September 2024 
1 October 2025† 
Enrolment
  Eligibility X
  Allocation X
Intervention
  HPV arm (CYT+HPV) <—> <—>‡ <—> 
  Present programme arm 
(CYT)
<—> <—> <—> 
Assessment
  Baseline screen X
  Second screen X
  Third screen X
  Final X
*All women born in 1994 living in Denmark in January 2017 were randomly allocated to HPV or present programme arm.
†End-of-study allowing for 1 year extra for women followed up due to abnormal cytology in former screening rounds.
‡Women with positive HPV test and normal cytology at baseline are retested after 3 years for both HPV and cytology.
CYT, cytology; HPV, human papillomavirus; SPIRIT, Standard Protocol Items: Recommendations for Interventional Trials.
Table 2 Number of eligible women residing in the 
geographical areas covered by Trial23
Participating region
Number of 
23-year-old 
women
Central Denmark 9242
North Denmark 3895
Zealand 3705
Southern Denmark (Soenderborg and Esbjerg) 2082
Total 18 924
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Patient and public involvement
The research question was developed in response to 
discussions in Denmark about future screening of 
HPV-vaccinated women. No representative of patient 
organisations participated in the design of the study. The 
results will be disseminated to women and healthcare 
authorities.
EtHICs And dIssEMInAtIon
Ethics
The study is a method study and therefore not notifiable 
to the ethical committees, and informed consent is not 
required. In this study, all women are screened according 
to routine practice with cytology every 3 years as in the 
present screening programme and all receive usual care. 
The two screening schedules are compared without 
affecting the screening programme, and there will be no 
change for the individual woman. In order to avoid confu-
sion, general practitioners and women are, therefore, not 
informed about the HPV test. Handling and storage of 
data were approved by the Danish Data Inspective Agency 
(SUND-2016–22).
dissemination
The study protocol is registered at  ClinicalTrials. gov 
(NCT03049553) and is made public in this protocol 
paper. Final and baseline results will be published in 
peer-reviewed, international open-access journals, listing 
authors according to authorship guidelines. Publication 
will be independent of results. Trial data will be deposited 
in the Danish Data Archive after end of study. Access to 
the data will follow the rules of the archive.27
dIsCussIon
In Denmark, the first birth cohorts of women offered 
HPV vaccination as girls are currently entering the 
cervical screening programme. The purpose of Trial23 is 
to test a new, less intensive screening scheme for these 
women than the one currently offered in Denmark. The 
intention is to guide decision makers on future screening 
of HPV-vaccinated birth cohorts.
In Trial23, the focus is on the HPV-negative women who 
can benefit from a longer screening interval. Cytology is 
chosen as triage method, because it is in routine use in 
the pathology departments and of good diagnostic quality 
in Denmark.
Trial23 is undertaken as a method study. Originally, we 
planned for a public health trial with randomisation to 
either the new or the current screening scheme. Such 
public health trials have been undertaken in the other 
Nordic countries. In a Swedish trial, women aged 56–60 
years were randomly invited to the present cytology-based 
screening or a new HPV-based screening scheme. The 
study was approved by the ethical committee who 
regarded participation in screening as consent.28 Like-
wise, in Finland women aged 25–65 years were randomly 
invited for the present cytology-based screening or a new 
HPV-based screening. The local ethical committees and 
national authorities deemed that informed consent was 
not necessary because the trial was part of the routine 
screening programme.29 In Denmark, it was not possible 
to get permission for such a trial.
strengths and limitations
The major limitation of the method study design is that 
a 6-year screening interval in the HPV arm has to be esti-
mated and that we have to account for the HPV-negative/
cytology positive samples that would not have been found 
by primary HPV screening with cytology triage.
However, this design gives us the opportunity to eval-
uate a new screening scheme without changing the 
screening programme. Moreover, informed consent 
is not required, which is expected to ensure routine 
screening coverage and limited selection. It is also a 
strength that the study is undertaken within the existing 
screening programme, because the results reflect imple-
mentation directly.
As there is no real intervention, randomisation would 
not have been needed. However, the decision from 
the Ethical Committee not to allow randomisation of 
the screening test without informed consent came at a 
late stage, where the organisation and resource alloca-
tion were already in place. At that time, we could not 
double the number of needed HPV tests neither could 
we exclude participating laboratories. Therefore, we 
kept randomisation of the supplementary HPV test. 
The randomisation will furthermore allow for check of 
a possible difference in the cytology reading between 
the HPV and the cytology arms. All women are from 
the same birth cohort and examined in the same 
calendar period. However, we are not able to adjust for 
HPV status at the time of vaccination and risk factors 
such as number of sexual partners and smoking habits. 
Misclassification of codes in the national registers are 
of course present, but there is no reason to believe that 
it will introduce bias. In primary HPV screening with 
cytology triage, the HPV status is known before the 
cytology is read. However, our study is embedded in the 
routine procedure in five pathology laboratories with 
primary cytology screening involving many laboratory 
technicians and pathologists. In some laboratories, the 
HPV status is known before the cytology reading, while 
in other laboratories, cytology is read prior to the 
HPV testing.
Perspectives
There is no international consensus on how to screen 
HPV-vaccinated women, and Denmark is one of the first 
countries to face this challenge. However, Australia imple-
mented HPV vaccination already in 2007 and will in 2017 
implement primary HPV screening with partial geno-
typing and cytology triage every 5 years for HPV-vaccinated 
and unvaccinated women aged 25–69 years. COMPASS (a 
Randomised Controlled Trial of Primary HPV Testing for 
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Cervical Screening in Australia) running in parallel aims 
to compare the new screening programme to cytology 
every two and a half years.10 In addition, a consensus on 
cervical screening in HPV-vaccinated women has been 
reached in Italy,30 where HPV vaccination started in 2008. 
Italy will change to primary HPV screening in 2021, when 
the first birth cohorts of women HPV vaccinated at age 
12 years enter the screening programme. Age at start of 
screening will change from the current 25 to 30 years, 
and the new screening protocol will be used only for 
vaccinated women until herd immunity is sufficient for 
all women to receive the same screening regardless of 
vaccination status.
In Denmark, the next seven birth cohorts of women 
entering the cervical screening programme were 
offered HPV vaccination at age 12–13 years with high 
coverage around 90% for first dose.20 However, recently 
HPV vaccination coverage has dropped in Denmark 
due to public concern about possible side effects.31 
Coverage is now 46% for first dose for girls born in 
2004.20 Japan has abandoned HPV vaccination because 
of attention to possible side effects,32 and decreasing 
coverage is at present also observed in the Netherlands33 
and Ireland.34 If HPV-vaccination coverage regains 
its former high level in Denmark, the same screening 
scheme would be applicable for all women because of 
high herd immunity. However, if coverage stays low, a 
similar approach as the Italian with different screening 
schemes for vaccinated and unvaccinated women may 
be considered.
trIAl stAtus
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